Radioisotopes for the palliation of metastatic bone cancer: a systematic review
IG Finlay, MD Mason, M Shelley - The lancet oncology, 2005 - thelancet.com
Summary Strontium-89 and samarium-153 are radioisotopes that are approved in the USA
and Europe for the palliation of pain from metastatic bone cancer, whereas rhenium-186 and …
and Europe for the palliation of pain from metastatic bone cancer, whereas rhenium-186 and …
Bone-seeking radionuclides for therapy
VJ Lewington - Journal of nuclear medicine, 2005 - Soc Nuclear Med
Systemic therapy using bone-seeking radiopharmaceuticals has clear advantages for the
treatment of multisite metastatic pain. Evidence supporting the use of β-particle, electron …
treatment of multisite metastatic pain. Evidence supporting the use of β-particle, electron …
Options to meet the future global demand of radionuclides for radionuclide therapy
T Das, MRA Pillai - Nuclear medicine and biology, 2013 - Elsevier
Nuclear medicine continues to represent one of the important modalities for cancer
management. While diagnostic nuclear medicine for cancer management is fairly well …
management. While diagnostic nuclear medicine for cancer management is fairly well …
Palliative treatment of metastatic bone pain with radiopharmaceuticals: A perspective beyond Strontium-89 and Samarium-153
Purpose The present review article aims to provide an overview of the available
radionuclides for palliative treatment of bone metastases beyond 89 Sr and 153 Sm. In …
radionuclides for palliative treatment of bone metastases beyond 89 Sr and 153 Sm. In …
Radioisotopes for metastatic bone pain
MR i Figuls, MJ Martinez‐Zapata… - Cochrane Database …, 2011 - cochranelibrary.com
Background This is an update of the review published in Issue 4, 2003. Bone metastasis
cause severe pain as well as pathological fractures, hypercalcaemia and spinal cord …
cause severe pain as well as pathological fractures, hypercalcaemia and spinal cord …
Use of radionuclides for the palliation of bone metastases
AJB McEwan - Seminars in radiation oncology, 2000 - Elsevier
Pain palliation with bone-seeking radiopharmaceuticals is an effective and cost-effective
management tool in patients with advanced cancer metastatic to bone. Strontium-89 …
management tool in patients with advanced cancer metastatic to bone. Strontium-89 …
Bone-targeting radiopharmaceuticals including radium-223
D Brady, CC Parker, JM O'Sullivan - The Cancer Journal, 2013 - journals.lww.com
Bone-seeking radionuclides including samarium-153 ethylene diamine tetramethylene
phosphonate and strontium-89 have been used for decades in the palliation of pain from …
phosphonate and strontium-89 have been used for decades in the palliation of pain from …
Treatment of bone metastasis with bone-targeting radiopharmaceuticals
JY Choi - Nuclear medicine and molecular imaging, 2018 - Springer
Bone is a common metastatic site of cancer. Bone metastasis reduces life expectancy and
results in serious symptoms and complications such as bone pain, pathological fractures …
results in serious symptoms and complications such as bone pain, pathological fractures …
Recent advances in radionuclide therapy
S Srivastava, E Dadachova - Seminars in nuclear medicine, 2001 - Elsevier
A variety of radionuclides continue to be investigated and/or clinically used for different
therapeutic applications in nuclear medicine. The choice of a particular radionuclide with …
therapeutic applications in nuclear medicine. The choice of a particular radionuclide with …
Teletherapy and radiopharmaceutical therapy of painful bone metastases
EB Silberstein - Seminars in nuclear medicine, 2005 - Elsevier
Bone pain from metastatic disease is most common in cancers of the breast, prostate, and
lung. Despite the World Health organization algorithm for treating such pain, the outcomes …
lung. Despite the World Health organization algorithm for treating such pain, the outcomes …